NASDAQ$ADPT
Adaptive Biotechnologies Corporation · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported an 83% increase in revenue compared to the second quarter of the prior year.
Adaptive Biotechnologies reported a strong second quarter with significant revenue growth, driven by sequencing and development revenue. The company is also making progress in its immune medicine platform, with emerging data expected to monetize for multiple opportunities.
- Revenue of $38.5 million for the second quarter 2021, representing an 83% increase from the second quarter 2020
- clonoSEQ clinical sequencing volume in the second quarter 2021 grew 75% versus prior year and 15% over the first quarter of 2021
- Signed a license agreement with Vaccibody to leverage Adaptive Biotechnologies’ T-cell data to inform the development of a T-cell based SARS-CoV-2 vaccine
- Signed an agreement with Moderna to use immunoSEQ T-MAP COVID to measure the T-cell response to their second generation COVID vaccine and their Zika vaccine
Headline financials
Revenue & EPS history
Adaptive Biotechnologies · Revenue · Quarterly
$38.5M
Revenue by segment
Adaptive Biotechnologies · $38M total across 2 segments · Q3 2023
- MRD Business$24.7M+23.5%65.0%
- Immune Medicine Business$13.3M-52.3%35.0%
Forward guidance
Adaptive Biotechnologies expects full year 2021 revenue to be in the range of $148 million to $155 million, representing 54% growth at the mid-point of the range over full year 2020 revenue. This compares to Adaptive Biotechnologies’ previous outlook of $145 million to $155 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+1.3%
Avg return
Earnings day
+0.0%
Avg return
5 days after
-0.9%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+33.2%
Q1 2025
Best reaction
-22.2%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -1.9% | +22.6% | |
| Q4 2025 | -4.3% | -5.2% | -9.8% | |
| Q3 2025 | -4.8% | -6.8% | -5.2% | |
| Q1 2025 | +33.2% | +19.7% | +29.3% | |
| Q4 2024 | -3.2% | +6.8% | -6.7% | |
| Q3 2024 | +1.2% | +3.1% | +9.0% | |
| Q2 2024 | -5.5% | +1.3% | +3.3% | |
| Q1 2024 | -1.2% | +8.7% | +21.1% | |
| Q4 2023 | +9.4% | +6.4% | -10.5% | |
| Q3 2023 | -22.2% | -9.3% | +4.4% | |
| Q2 2023 | -15.5% | -18.8% | -17.5% | |
| Q1 2023 | -8.3% | -5.8% | +6.4% | |
| Q4 2022 | +15.4% | +9.3% | -3.3% | |
| Q3 2022 | +13.2% | -0.9% | +14.1% | |
| Q2 2022 | +19.3% | +22.8% | -8.4% | |
| Q1 2022 | -1.1% | -19.2% | -22.5% | |
| Q4 2021 | +5.3% | -8.0% | -15.3% | |
| Q3 2021 | +6.7% | +5.7% | -26.6% | |
| Q2 2021 | +4.8% | -2.4% | +9.8% | |
| Q1 2021 | +0.9% | -11.2% | -1.0% | |
| Q4 2020 | -2.6% | +2.0% | -32.8% | |
| Q3 2020 | +8.0% | +2.1% | +14.9% | |
| Q2 2020 | -3.8% | +2.8% | +0.2% | |
| Q1 2020 | -6.7% | -0.2% | +9.9% | |
| Q4 2019 | -5.6% | -10.7% | -15.4% | |
| Q3 2019 | -3.7% | +0.7% | +11.8% | |
| Q2 2019 | +3.5% | +9.7% | -5.4% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro